Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients

NCT03190941 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

110

Enrollment

NIH

Sponsor class

Conditions

Pancreatic Cancer
Gastric Cancer
Gastrointestinal Cancer
Colon Cancer
Rectal Cancer

Interventions

DRUG: Cyclophosphamide
DRUG: Fludarabine
BIOLOGICAL: Anti-KRAS G12V mTCR PBL
DRUG: Aldesleukin

Sponsor

National Cancer Institute (NCI)